Doximity reported strong Q3 performance, driven by high pharma client demand. Click here to find out why DOCS stock has been ...

Doximity has been a top-rated stock at MAPsignals. That means the stock has unusual buy pressure and growing fundamentals. We ...

Doximity Inc (DOCS) reports a 25% revenue increase and unveils plans for continued client engagement and product innovation.

Healthcare professional network Doximity (NYSE:DOCS) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with ...

Doximity, Inc. is growing faster than even management expected while scaling costs and returning customers better than the ...

Goldman Sachs analyst David Roman raised the firm’s price target on Doximity (DOCS) to $80 from $58 and keeps a Neutral rating on the shares ...

What’s the full story? Baird is here to talk about FTNT, the stock that’s been oscillating between “rocket ship” and “meh” like a crypto bro trying to explain utility tokens. In 2024, FTNT was the ...

Raymond James raised the firm’s price target on Doximity (DOCS) to $83 from $65 and keeps an Outperform rating on the shares. Doximity’s Q3 ...

Doximity(NYSE:DOCS), a digital platform for U.S. medical professionals ... The company's net income jumped to $75.2 million, marking a 57% year-over-year increase. Margins also improved, with the ...

SAN FRANCISCO— Doximity , Inc. (NYSE:DOCS) director Yang Watkin Phoebe L. recently sold shares of the company's Class A common stock, according to a filing with the Securities and Exchange Commission.